Citeline Podcast Special: The Shifting Landscape For Drugs And Devices Post-Roe v. Wade

Citeline Podcasts

English - July 15, 2022 21:14 - 25 minutes - 14.2 MB - ★★★★★ - 24 ratings
Business News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Pink Sheet Podcast: Novavax Gets EUA, Califf Sets US FDA Departure, Hemophilia Patients Want REMS

Next Episode: Scrip’s Five Must-Know Things – 18 July 2022

Articles mentioned in this podcast:

US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application

Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC

OTC Switch For Daily Oral Contraceptive Brandished In Senate Health Care Policy Duel

Barriers To US OTC Emergency Contraceptive Sales Remain Despite Court Rebuke Of Restrictions

Expanding US OTC Switches Turns On Flexibility In FDA Drug Approval Process And For Consumers

Dual Rx/OTC Status In US ‘Additional Condition’ Switch Proposal: Necessary Or Questionable?

US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade
Mifepristone Access Imperiled By Supreme Court’s Draft Decision Overturning Abortion Rights
With Roe v. Wade In Rearview, What’s Next For Women’s Health

Telemedicine Among Sticky Wickets As Uncertainty Abounds Post-Roe v. Wade

Period-Tracking Apps Should Safeguard Data, Reassure Customers In Post-Roe Era